Mucin-type O-glycans decorate >80% of secretory and cell surface proteins and contribute to health and disease. However, dynamic alterations in the O-glycome are poorly understood because current O-glycomic methodologies are not sufficiently sensitive nor quantitative. Here we describe a novel isotope labeling approach termed Isotope-Cellular O-glycome Reporter Amplification (ICORA) to amplify and analyze the O-glycome from cells. In this approach, cells are incubated
Introduction
Protein glycosylation is an abundant post-translational modification and involved in diverse processes ranging from cell signaling to tissue homeostasis (Apweiler et al. 1999; Ohtsubo and Marth 2006; Steentoft et al. 2013 ). Normal glycosylation is disturbed in many diseases, making glycans a powerful biomarker to follow disease course, predict treatment and understand pathology (Ohtsubo and Marth 2006) . Ordinary sequencing of glycans requires chemical and/or enzymatic release followed by mass spectrometry (MS) (Cummings and Pierce 2014) . Although this provides valuable qualitative information, glycan release requires relatively large sample sizes, limiting glycomics in many important settings, and cannot easily be done to study signaling/metabolic changes associated with altered glycosylation.
Stable isotope labeling is a powerful approach to quantify changes in glycan expression. As in proteomics, glycans can be labeled after extraction with stable isotope tags, either by permethylation or reducing end tags, or prior to extraction by metabolic incorporation of heavy nitrogen (Gygi et al. 1999; Ong et al. 2002; Yuan et al. 2005; Alvarez-Manilla et al. 2007; Orlando et al. 2009 ). Since stable isotope labeling results in a mass shift, labeled and unlabeled samples can be mixed and analyzed by mass spectrometry to assess relative changes in glycan expression. While labeling at the reducing end results in fixed mass tags, permethylation or metabolic incorporation results in dynamic mass tags with mass shifts that depend on glycan size and composition, complicating analyses.
Mucin type O-glycans in O-GalNAc-linkage to Ser/Thr/Tyr residues decorate >80% of proteins that traverse the secretory apparatus and are altered in various human biological processes, such as leukocyte trafficking, and also in diseases, such as cancer and inflammatory bowel disease (IBD), but current strategies to assess these O-glycan structures and changes are limited Fu et al. 2011; Furukawa et al. 2013; Ju et al. 2013 Ju et al. , 2014 Steentoft et al. 2013; Kudelka et al. 2015 Kudelka et al. , 2016b . Because there are no enzymes capable of releasing complex-type O-glycans from proteins or peptides, analysis requires inefficient chemical release methods that result in glycan degradation and poor signal-to-noise (Furukawa et al. 2013) . Additionally, reduction of the reducing glycan to the alditol derivative during release prevents further labeling at the reducing end and in most cases reliance on dynamic mass tags for quantitative glycomics. To aid in O-glycan analysis, we recently developed a technology termed cellular O-glycome reporter/amplification (CORA) that bypasses glycan release and amplifies the O-glycome from cultured cells, resulting in 100-1000× increased sensitivity over traditional methods (Kudelka et al. 2016a) . In CORA, a peracetylated chemical O-glycan precursor (Ac 3 GalNAc-Bn) is added to cells, crosses the plasma membrane, is de-esterified, taken up into the Golgi apparatus, and modified by endogenous glycosyltransferases utilizing native sugar donors before being secreted for easy purification and MS analysis.
Here, we have modified CORA for quantitative glycomics by utilizing a stable isotope labeled Ac 3 GalNAc-Bn precursor with a deuterated benzyl group that is 7 Da heavier than its protonated counterpart. These D 7 heavy labeled Bn D7 -O-glycans can be mixed with light Bn H7 -O-glycans generated from cells for sensitive and reproducible relative quantification within a 10-fold linear range. We term this technology isotopic labeling with cellular O-glycome reporter/amplification (ICORA). Using this approach, we evaluated alterations in the O-glycome in colorectal cancer and identified specific differences in O-glycan biosynthesis. ICORA combines the advantages of fixed mass stable isotope labeling with glycome amplification for sensitive, high-throughput, comparative/quantitative cellular O-glycomics.
Results
Overview of isotopic labeling with cellular O-glycome reporter/amplification (ICORA)
Although CORA is a powerful tool to assess qualitative changes in Oglycosylation, we sought to introduce a heavy isotope label into Bn-α-GalNAc (Ac) 3 , which along with the unlabeled precursor can be used to assess quantitative changes in the glycome, similar to SILAC for proteomics (Ong et al. 2002) . We envisioned that a cell line undergoing condition A can be incubated with the light, unlabeled Ac 3 GalNAcBn H7 while the same cell line undergoing condition B can be incubated with the heavy, deuterium labeled Ac 3 GalNAc-Bn D7 precursor (Figure 1 ). Figure S1 , to form the heavy labeled Ac 3 GalNAc-Bn D7 precursor.
The Ac 3 GalNAc-Bn D7 precursor has a predicted mass 7 Da heavier than the unlabeled Ac 3 GalNAc-Bn H7 counterpart. We analyzed the heavy and light precursors by MALDI-MS and observed the expected masses of 460.3 m/z (Figure 2A ) and 467.3 m/z ( Figure 2B ), respectively, corresponding to [M+Na]+ ions. Importantly, when we mixed these two compounds in a ratio of 1:1 and performed MALDI, we obtained a ratio of peak intensities of L:H of approximately 1:1, indicating that the deuterated precursor ionizes similarly to the protonated precursor ( Figure 2C and D). -O-glycans from cell culture media as described, with an additional C18 purification step as detailed in the Methods section (Kudelka et al. 2016a ). Bn-O-glycans were then permethylated and analyzed by MALDI-TOF-MS. Light ( Figure 3A ) and heavy-labeled Bn-O-glycans ( Figure 3B ) produced a similar pattern of core 1 and 2-based structures with 0-2 sialic acids, 0-1 fucose, and LacNAc extension on the core 2 branch.
To further compare relative abundances, we overlaid heavy and light spectra and found that they were nearly identical ( Figure 3C and D). Thus, Ac 3 GalNAc-Bn H7 and Ac 3 GalNAc-Bn D7 are processed similarly in cells.
Comparative O-glycomics in adherent and suspension cells
We next asked whether we could mix Bn D7 -O-glycans and Bn
H7
-Oglycans derived from the heavy and light precursors to provide a semi-quantitative analysis for comparative O-glycomics. We incubated adherent (HEK-293, Figure 4A ) or suspension cells (MOLT-4, Figure 4B ) with 50 μM Ac 3 GalNAc-Bn H7 or Ac 3 GalNAc-Bn D7 for 3 days, collected media, and mixed heavy or light-labeled media from the same cell line in a 1:1 ratio before purification, permethylation, and MS analysis of Bn-O-glycans. We compared ratios of Bn respective isotopic distributions. Thus, ICORA is an advantageous technology for comparative O-glycomics.
Semi-automated detection of O-glycans with ICORA
A major goal of computational glycomics is automated peak assignment of MS spectra. A variety of tools have been developed for N-glycans with less success for O-glycans (Goldberg et al. 2005 North et al. 2009 ). One of the major challenges for O-glycans is that signal-to-noise and peak abundances are poor. We partially addressed this with CORA by amplifying the glycome, introducing a unique Bn mass tag, and permitting a vehicle only negative control. However, low abundance peaks are sometimes still challenging to assign. ICORA addresses this limitation by introducing a heavy isotope label to more definitively identify O-glycans by a 7 Da mass shift. As outlined in Supplementary data, Figure S2 , we performed all analyses in biological triplicate, spotted permethylated glycans from each biological replicate in technical triplicate, and then performed MS. Mass lists were then automatically extracted, filtered based on a theoretical mass list of all possible monosaccharide combinations, evaluated for a 7 Da shift, and then manually assessed to convert the m/z corresponding to some combination of monosaccharides to a likely O-glycan structure. All steps except for the last step were fully automated, successfully annotating Oglycans from the MS spectra.
Sensitive detection of small changes in O-glycan abundance
One of the potential strengths of our approach is to detect small changes in the relative abundance of glycans within a complex repertoire. To test this, we incubated HEK-293 cells with 50 μM of Ac 3 GalNAc-Bn H7 or Ac 3 GalNAc-Bn D7 for 3 days and mixed media from the two conditions in ratios of 1:9, 1:3, 1:1, 3:1 and 9:1 ( Figure 5 ). We normalized the ratios of L:H for all mixtures to the 1:1 mixture and compared the theoretical to experimental L:H intensities across nine major glycans. We only evaluated nine glycans here instead of the 16 described previously because minor peaks of the Bn D7 and Bn H7 tagged glycans were undetectable for the 1:9 and 9:1 mixtures for 7 of the prior 16 glycans, reflecting their reduced abundance in the HEK-293 O-glycome. We fitted a line comparing experimental (y) to theoretical (x) L:H intensities and found that these values highly correlated, with a slope ranging from y = 0.93x to y = 1.25x ( Figure 5A and Supplementary data, Figure S2 ). In addition to evaluating normalized data from three biological replicates ( Figure 5A , Supplementary data, Figure S2 ), we also evaluated individual spectra and saw a clear shift in Bn 
Altered O-glycosylation in colorectal cancer
O-glycans play diverse roles in tumor biology, however, the precise changes associated with tumor metastasis are poorly understood due to a lack of sensitive, quantitative technologies for O-glycomics (Kudelka et al. 2015) . To address this, we applied ICORA to model colorectal cancer cell lines (Figure 6 and Supplementary data, Figure S4 ). SW480 and SW620 cells are derived from primary and metastatic colorectal cancer lesions from a single individual and retain some primary/metastatic features (Hewitt et al. 2000) . We performed ICORA on SW480 and SW620 cells in biological triplicate, normalizing SW480:SW620 L:H ratios to SW480:SW480 L:H ratios ( Figure 6A and Supplementary data, Figure S4 ). In total, we obtained 18 glycans for comparison, consisting of Core 1 and 2-based O-glycan structures and diverse terminal epitopes, including possible GalNAc, GlcNAc, α-Gal, blood group A, blood group B, polyLacNAc (-3Galβ1-4GlcNAcβ1-) n , unmodified termini, sialylated termini, highly fucosylated structures, and LDNF (GalNAcβ1-4 [Fucα1-3]GlcNAcβ1-R). Although SW480/620 cells are classified as blood group A cells, trace levels of B-blood group have been previously demonstrated (Dahiya et al. 1989) . Since α-Gal is an unusual structure in human cells, especially those containing blood group B, we performed MALDI-MS/MS on glycan 1421 m/z in SW480 cells. Although we did not obtain linkage information and 1421 m/z was a relatively minor peak introducing some uncertainty in the MS/MS analysis, we found multiple fragments consistent with unfucosylated terminal Gal-Gal in a structure likely corresponding to Fucα1-2Galβ1-3[Galα1-3Galβ1-4GlcNAcβ1-6]GalNAcα1-Bn (Supplementary data, Figure S5 , Table S1 ). After assessing the repertoire of O-glycans in SW480 and SW620 cells, we evaluated changes in glycosylation. Of the 18 glycans analyzed, seven increased in SW620s (m/z: 956, 973, 1014, 1044, 1218, 1248, 1317) , three decreased (m/z: 1258, 1870, 2465), and eight were unchanged (m/z: 840, 1392, 1405, 1421, 1493, 1667, 1579, 1841) (Figure 6A and B). Compared to SW480 cells, SW620 cells exhibited a reduction in larger glycans and a corresponding increase in smaller O-glycans. Reduced glycans were core 2-based, fucosylated (1-3 fucose), but not sialylated. In contrast, increased glycans were core 1 or core 2-based and contained unmodified, sialylated (1-2 Sia), and fucosylated (1 fucose) termini. The compositions of the increased glycans were consistent with blood group A containing structures, which were not present in the unchanged or reduced group, while compositions consistent with blood group B structures were present in all groups, and LDNF, which was only observed on one structure, was reduced in SW620s. Collectively these data provide a mixed picture in which SW620 cells exhibit reduced glycan size but increased complexity of glycan termini compared to SW480 cells.
To explore the transcriptional basis for altered O-glycosylation, we performed qRT-PCR transcript analysis of O-glycogenes predicted to be important in regulating the types of O-glycans found in the above analyses, including C1GalT1 (T-synthase), C1GalT1C1 (Cosmc), GCNT1-4, B3GnT3 and 6, ST3Gal1, ST3Gal2, ST3Gal3, ST3Gal4, ST6GalNAc1, ST6GalNAc2, ST6GalNAc3, ST6GalNAc4, and Fut1, Fut2, Fut3, Fut4, Fut5, Fut6, Fut7 and Fut9 ( Figure 6C ). Compared to SW480 cells, SW620 cells exhibited a change in 6 of the 24 transcripts with an increase in GCNT2 and GCNT3 and a reduction in ST3Gal1, ST6GalNAc2, Fut1 and Fut6. GCNT2 produces I antigen, which was not observed in SW480/ 620 O-glycans. In contrast, the other altered transcripts encode enzymes that synthesize structures present on SW480/620 O-glycans. GCNT3 produces Core 2, ST3Gal1 and ST6GalNAc2 produce sialyl and disialyl Core 1 (with addition of NeuAc on Gal and GalNAc, respectively), and Fut1 and Fut6 fucosylate galactose (to form Blood group-H) and GlcNAc, respectively. Based on transcriptional changes alone, these would predict increased Core 2-based structure (ST3Gal1 competes with GCNT3), reduced monosialyl and disialyl Core 1, and reduced fucosylation. Transcripts and structures correlate for fucosylation; however, other alterations in the transcriptome do not fully predict changes in the glycome. Therefore, additional factors such as Golgi architecture, glycoprotein flux, and transcript stability/turnover probably also help to regulate the colorectal O-glycome. Thus, these results demonstrate that O-glycosylation in SW480 versus SW620 colorectal cancer cells differ in specific O-glycan structures and gene expression.
Discussion
Here, we provide a novel stable isotope-based metabolic strategy to explore comparative O-glycomics through chemical synthesis using a stable isotope labeled O-glycome precursor, Ac 3 GalNAc-Bn D7 .
Addition of a light and heavy precursor to cells followed by mixing and analysis of differentially labeled Bn-O-glycans allows quantitative comparisons of O-glycan abundance in the same spectrum. Although metabolic stable isotope labeling has been previously applied to glycomics (Orlando et al. 2009 ), ICORA is the first to combine glycome amplification with stable isotope labeling for comparative O-glycomics. Thus, we can now study metabolic, signaling, and transcriptionally dependent changes in O-glycosylation in living cells. This approach opens the way to identifying specific inhibitors and signaling regulators of O-glycosylation. The importance of these studies arises from the growing evidence that O-glycans are an abundant post-translational modification and contribute to regulating many biological processes (Steentoft et al. 2013; Kudelka et al. 2015) . However, the structures normally present in cells and how they change in disease are not well understood. Part of the problem in studying O-glycans in cultured cells is that Oglycans are often relatively low in abundance, small in size, and a single plate of cultured cells does not provide enough material for robust glycan analysis and sequencing. Thus, ICORA provides many advantages. In addition to analyzing different cell populations or cells undergoing different treatment conditions, ICORA can also be used for semi-automated glycomics. The signal-to-noise and mass accuracy of MALDI-MS for O-glycans usually necessitates manual interrogation. However, we found that by analyzing cells incubated with a light and heavy O-glycan precursor that we could extract mass lists and filter those based on monosaccharide compositions and a 7 Da mass shift. Together these two criteria were sufficient for automated peak extraction and assignment.
Using this approach, we were able to identify LDNF as an epitope on O-glycans in colorectal cancer cells. This structure is abundant on parasitic glycans, but infrequent in mammals (Prasanphanich et al. 2014) . A recent report observed LDNF in gastric tissues (Ikehara et al. 2006; Jin et al. 2017) , which is consistent with our results and suggests that LDN and its fucosylated derivative LDNF may be a common but unappreciated feature of the human GI tract. Given that LDN-type glycans are immunosuppressive on parasites and glycodelin, it is tempting to speculate that they may contribute to the tolerogenic environment of the human gut (Kawar et al. 2005) .
Through mixing experiments we clearly showed that ICORA is able to reproducibly detect small changes <10-fold in glycan abundance. We applied this to evaluate altered O-glycosylation in two colorectal cancer cell lines derived from the same individual and found that SW620 cells had reduced glycan length and increased epitope diversity compared to SW480 cells. Except for fucosylation, these changes were not correlated with changes in gene transcript abundances, highlighting the complexity of glycome regulation (Cummings and Pierce 2014) . Thus, ICORA and other highthroughput glycomics and glycoproteomics technologies will be critical in understanding the biological roles of glycans in different cells and tissue and offer significant advantages over transcriptomics, which do not fully predict the glycome. Importantly, some of our findings compared well with prior studies, including an increase in sialyl-T and Core 2-sLe structures as well as a reduction in ST6GalNAc2, changes shown to promote invasion/metastasis (Holst et al. 2015; Jia et al. 2017) . Given the widespread impact of other quantitative -omics, this new approach combining glycome amplification and metabolic stable isotope labeling in ICORA will provide a much needed tool for dissecting the cellular O-glycome.
This approach has some limitations, including the need to use living cells for metabolic labeling, the need of cells to synthesize enough material in secretions for identification, and the potential for cells to secrete enzymes that may alter or destroy glycans once secreted. In regard to the latter, we showed previously that secreted Bn-O-glycans are stable in culture media (Kudelka et al. 2016a) , indicating that there is little if any degradation of glycans upon secretion. Notably, although we analyzed secreted Bn-O-glycans from media, we previously showed that these structures mirror those obtained by traditional analyses of whole cell lysates, including cell surface and intracellular structures. This follows from the fact that our O-glycan precursors traverse the same pathways as cell surface and secreted glycoproteins. Although ICORA is unique in providing a 7 Da mass shift, it does not eliminate many limitations of glycan structural analysis by mass spectrometry such as MS/MS of low abundance species or mass accuracy of MALDI versus electrospray ionization. Thus, non-MS-based approaches are still important for structural confirmation of biologically significant glycans. Finally, the precise quantification of secreted Bn-O-glycan, which relies on weak absorbance in the UV range, is difficult and we are developing MS standards to aid in the quantification in the future.
The information that can be obtained by the ICORA method has important implications. Studies of living cells in culture, and perhaps in organoids, using ICORA could provide insights into changes in Oglycosylation associated with cell growth, cell adhesion, matrix interactions, growth factors and other biological signaling pathways. As we described previously, as few as 10 4 cells may be used in this approach, thus allowing semi-quantitative and qualitative studies to be performed that have not been approachable by conventional methods. Also, the isolated and differently labeled Bn-O-glycans can be useful standards and reagents for other studies, since it is possible to define a standard isotope-labeled set of Bn-O-glycans that can be stored indefinitely.
Materials and methods

Cell culture
HEK-293 cells were a kind gift from Dr. Henrik Clausen (University of Copenhagen). MOLT-4, SW480, SW620 cells were purchased from ATCC. All cells were cultured in 10% fetal bovine serum and 2% penicillin-streptomycin. HEK-293, MOLT-4, and SW480/ SW620 were cultured in DMEM (Corning), RPMI (Corning), and L-15 (Corning), respectively. All were grown on polystyrene except MOLT-4 cells that were grown in suspension. HEK-293, SW480 and SW620 cells were seeded at 10 5 cells/mL in 1 mL of media in a 12-well dish (Figures 3, 4, 6 ) or in 5 mL of media in a T25 flask ( Figure 5 ). Compound was added the next day in 2 mL ( Figures 3, 4 , 6) or 5 mL ( Figure 5 ) of fresh media. MOLT-4 cells were seeded at 5 × 10 5 cell/mL in 1 mL of media in a 12-well dish ( Figure 4 ) and compound was added the next day in an additional 1 mL of fresh media to a final volume of 2 mL. All cells were then incubated with compound for 3 days prior to collection, purification, permethylation and MS analysis.
Compounds
GalNAcαBn was purchased from Sigma and peracetylated as described (Kudelka et al. 2016a ) to generate Ac 3 GalNAc-Bn. Ac 3 GalNAc-Bn D7 was synthesized from Bn D7 OH (Supplementary data, Figure S1 ). Both were suspended at 50 mM concentration in DMSO and stored at -20°C until use. Stock solutions were diluted in cell culture media to a final concentration of 50 μM to incubate with cells.
Glycan purification
Media was collected from cells incubated with 50 μM Ac 3 GalNAcBn or Ac 3 GalNAc-Bn D7 for 3 days and Bn-O-glycans or Bn
D7
-Oglycans were purified with a centrifugal filter using a 10 kDa high mass cut-off (Amicon) followed by reverse phase C18 (Waters) chromatography as described (Kudelka et al. 2016a ). Bn-O-glycans or Bn D7 -O-glycans were either directly purified from media or mixed in different ratios prior to purification. In Figure 4 , all of the 2 mL of media collected from cells incubated with Ac 3 GalNAc-Bn H7 or Ac 3 GalNAc-Bn D7 was mixed together at a 1:1 ratio prior to purification. In Figure 5 , 5 mL of media was collected from cells incubated with Bn H7 -O-glycans or Bn D7 -O-glycans and mixed together at a ratio of 1:9, 1:3, 1:1, 3:1 and 9:1 to a final volume of 1 mL. Three mL of PBS was then added to make a final volume of 4 mL prior to purification.
Glycan permethylation
After purification from media, Bn H7 -O-glycans and Bn D7 -O-glycans were permethylated by DMSO/NaOH slurry and methyl iodide as described (Kudelka et al. 2016a) . Following chloroform extraction, permethylated Bn H7 -O-glycans and Bn D7 -O-glycans were further purified by reverse phase C 18 chromatography, washed with an acetonitrile step-gradient, eluted by 50% acetonitrile, and dried by vacuum centrifugation (Jang- Lee et al. 2006) . This substantially increased signal-to-noise compared to chloroform extraction alone.
Mass spectrometry
Permethylated Bn H7 -O-glycans and Bn D7 -O-glycans were suspended in 10 μL of methanol (Jang- Lee et al. 2006) . 0.5 μL of glycan suspension was mixed 1:1 with 0.5 μL of 20 mg/mL 2,5-dihydrobenzoic acid (Sigma) in 80% methanol on a Bruker AnchorChip 384 BC target plate, air dried, and analyzed by MALDI-TOF mass spectrometry using Bruker Daltonics ultrafleXtreme TOF-TOF system and flexControl software. Five thousand shots were collected in reflectron positive (RP) mode in the 800-5000 m/z range for each spot after calibration by standard peptide mixture. Molecular ions correspond to [M+Na] + .
Glycan analysis
Each experiment was performed in biological triplicate and each sample was spotted in technical triplicate to control for spot-to-spot variations.
Mass peaks were identified and filtered in a semi-automated manner to identify those corresponding to O-glycans. Briefly, major mass peaks were identified from Bruker Daltonics flexAnalysis software using automatic peak picking (default settings) and compared against a glycan mass library generated from random combinations of monosaccharides. Bn-O-glycans generated from Ac 3 GalNAc-Bn H7 versus Ac 3 GalNAc-Bn D7 were identified and filtered by a 7 Da mass shift.
Putative glycan peaks were manually verified and assigned putative structures based on biosynthetic knowledge. Peak abundances were extracted and statistically analyzed as described in Statistics.
Representative spectra were generated from mMass 5.5.0 (Strohalm et al. 2008 ) and overlaid with glycan "cartoon" representations from Glycoworkbench (Ceroni et al. 2008; Damerell et al. 2012) .
RNA isolation and qRT-PCR analysis
Colorectal cancer cells were harvested, flash-frozen in liquid nitrogen, and stored at -80°C until use. Total RNA isolation and cDNA synthesis on four biological replicates of each cell type was carried out as described previously (Nairn et al. 2007 ). The qRT-PCR reactions were performed in triplicate for each gene analyzed using primer pairs listed in Supplemental Table 2 . Amplification conditions and data analysis was performed as described previously (Nairn et al. 2010) . Briefly, Ct values for each gene were normalized with the control gene, RPL4, prior to calculation of relative transcript abundance followed by statistical analysis with the Mann-Whitney test using GraphPad InStat software.
Statistics
Ratios of abundances of Bn
H7
-O-glycans to Bn D7 -O-glycans were averaged from technical triplicates to obtain a mean spot for each glycan. Statistics were performed on the mean spot from three biological replicates with GraphPad Prism or R program language as indicated in the figure legends.
Supplementary data
Supplementary data is available at Glycobiology online.
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